WebMD article details the effects of long COVID on mental health and interviews BRAINN researcher (and COVID specialist) dr. Clarissa Yasuda.
BRAINN at NatureResearch: “A new model for brain research”
At the Brazilian Research Institute for Neuroscience and Neurotechnology (BRAINN), researchers combine disciplines to find new ways to address the age-old conditions of epilepsies and strokes. Read more…
Devices help predict seizures and treat patients with epilepsy
Agência FAPESP interviews the Australian researcher Mark Cook on implantable devices aimed at controlling epilepsy.
BRAINN Congress highlights new technologies and discusses public health
Article published in the Unicamp Portal highlights the technological and scientific advances discussed at the 6th BRAINN Congress.
SUS to incorporate Exoma sequencing to diagnose intellectual disability
Decision to adopt the exam was guided by a technical-scientific opinion prepared by a doctorate from FCM-Unicamp, working with researchers from CEPID BRAINN.
Brazilians create system that moves wheelchair using facial expressions
Website “VivaBem”, related to one of Brazil´s biggest internet providers, interviews the researcher Paulo Gurgel Pinheiro, who joined CEPID BRAINN as an associate researcher on professor Eleri Cardozo´s team. Read more…
Brazilian scientist creates wheelchair system ‘moved by smiles’
Researcher Paulo Pinheiro´s invention was exhibited at the world´s largest technology fair. Pinheiro was part of BRAINN as an associate researcher on Professor Eleri Cardozo‘s team.
BRAINN and Enigma: International partnership enables advances in research into debilitating diseases
By Maria Fernanda Ziegler, in New York | Agência FAPESP – Research conducted by the ENIGMA international consortium has studied the brains of more than 3,800 volunteers from several countries for the purpose of discovering similarities and differences between brain anatomy and different types of epilepsy. The goal is to seek markers that help in disease prognosis and treatment.
Another group of researchers is using analysis of patient levels of two microRNAs, genetic markers that serve as indicators of Amyotrophic Lateral Sclerosis (ALS) – the disease that affected British physicist Stephen Hawking.
A third study, also on epilepsy, suggests that deregulation of the NEUROG2 gene is related to the appearance of focal cortical dysplasia – a brain defect that is one of the most common causes of medically refractory epilepsy. With identification of this biomarker, it will be possible to indicate various treatments such as surgery for patients who suffer from drug-resistant epilepsy.
The three studies include participation by researchers from the Brazilian Institute of Neuroscience and Neurotechnology (BRAINN), a Research, Innovation and Dissemination Center (RIDC) funded by FAPESP, headquartered at the University of Campinas (Unicamp).
“Our objective is to develop new methods and techniques to improve our understanding of how to treat and prevent debilitating diseases and conditions that affect the brain, such as epilepsy and cerebral vascular accident (CVA). We are also interested in studying diseases that cause dementia or motor problems, as in the case of ALS,” said Iscia Cendes, principal investigator of BRAINN, in a talk given at FAPESP Week New York – held at the City University of New York (CUNY) November 26-28, 2018, the meeting involved Brazilian and U.S. researchers with the aim of strengthening research partnerships.
“Human beings, just like the diseases we are studying, are very complex. That is why we think that participation in consortia and partnerships is the best way to leverage our discoveries,” Cendes said.
The researcher said that since the establishment of BRAINN, in 2013, the number of big data projects in neuroscience has increased. Examples of these types of projects include the BRAIN initiative in the United States, the Human Brain Mapping initiative in Europe, the Alzheimer’s Disease Neuroimaging Initiative (ADNI), the International League Against Epilepsy (ILAE) and the ENIGMA consortium.
“Big data efforts have become the modus operandi of neuroscience, replacing small-scale science based on hypotheses,” she said.
It is no coincidence that Cendes says that the next BRAINN projects will include advancing longitudinal studies. “That is one of our strong points as a group,” she added.
Another BRAINN proposal is reducing the gap between basic biological research and its clinical application. One of the lines of research for that purpose is the Brazilian Initiative on Precision Medicine (BIPMed), an initiative created in 2015 by five FAPESP-funded RIDCs.
“The first BIPMed product was creation of a database of genomes corresponding to healthy individuals and those with specific diseases. There are currently more than 900,000 genetic variants deposited in the database,” she said.
The database includes deposits of genomes related to epileptic encephalopathies, craniofacial anomalies, breast cancer, hereditary deafness and neurofibromatosis, and in 2019, sequences related to lupus will be added.
Two of BRAINN´s spin-off companies talk about entrepreneurship for ‘Jornal da Unicamp’
We translate Unicamp´s reports on the companies Bioxthica and Hoobox, CEPID BRAINN´s spin-off research projects.
Watch: Brazil´s main TV station highlights research on brain diagnostics
Watch here the ‘Jornal da EPTV’´s report and the interviews with BRAINN researchers Letícia Rittner, Mariana Bento and Li Li Min. Read more…